2015
DOI: 10.1016/j.ajo.2015.07.002
|View full text |Cite
|
Sign up to set email alerts
|

Reply

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 2 publications
0
3
0
Order By: Relevance
“…Acute-onset infectious endophthalmitis continues to be the most feared and significant complication of intravitreal injections, causing severe and potentially irreversible vision loss and is defined by an onset within 6 weeks after surgical intervention [6-8]. Each injection of anti-VEGF agents such as bevacizumab, ranibizumab, or aflibercept carries a small associated risk of endophthalmitis with a reported incidence of endophthalmitis after anti-VEGF injection between 0.01 and 0.32% [9-15].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Acute-onset infectious endophthalmitis continues to be the most feared and significant complication of intravitreal injections, causing severe and potentially irreversible vision loss and is defined by an onset within 6 weeks after surgical intervention [6-8]. Each injection of anti-VEGF agents such as bevacizumab, ranibizumab, or aflibercept carries a small associated risk of endophthalmitis with a reported incidence of endophthalmitis after anti-VEGF injection between 0.01 and 0.32% [9-15].…”
Section: Introductionmentioning
confidence: 99%
“…To date, all multicenter studies investigating postinjection endophthalmitis have been nationwide or regional only, including medical centers from a few specific countries such as France, the UK, and the USA [6, 7, 10-12, 14]. In these publications, injection settings and postinjection recommendations were mostly similar within countries or local regions due to guidelines set by the national regulatory agencies.…”
Section: Introductionmentioning
confidence: 99%
“…The strengths of the current study are (1) that it is one of the few to satisfy the "two-species" rule for establishing potential clinical efficacy, (2) it distinguishes between two competing hypotheses for how adult enucleation of the fellow eye enables recovery from amblyopia, and (3) the experiments demonstrate durable recovery from the effect of long-term MD after the end of the critical period. An injection of TTX (or equivalent) into the eye is not without risks that need to be carefully considered before contemplating human application (see, e.g., (Dossarps et al, 2015)). However, histological analysis of the cat retina and optic nerve revealed no deleterious effect of 10 days of TTX treatment (DiCostanzo et al, 2020), and the electrophysiological analyses and behavioral observations in the current study indicate complete functional recovery of vision in the injected eye.…”
Section: Discussionmentioning
confidence: 99%